(NASDAQ: MGX) Metagenomi's forecast annual revenue growth rate of -4.44% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.97%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.99%.
Metagenomi's revenue in 2025 is $33,768,000.On average, 3 Wall Street analysts forecast MGX's revenue for 2025 to be $1,216,186,206, with the lowest MGX revenue forecast at $619,672,075, and the highest MGX revenue forecast at $1,749,044,138.
In 2026, MGX is forecast to generate $1,557,737,743 in revenue, with the lowest revenue forecast at $619,672,075 and the highest revenue forecast at $2,552,253,248.